ROTH MKM initiated coverage on Verona Pharma with a new price target
$VRNA
Biotechnology: Pharmaceutical Preparations
Health Care
ROTH MKM initiated coverage of Verona Pharma with a rating of Buy and set a new price target of $68.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/28/2025 | $100.00 | Buy | TD Cowen |
| 4/21/2025 | $80.00 | Overweight | Cantor Fitzgerald |
| 1/10/2025 | $68.00 | Buy | ROTH MKM |
| 10/3/2024 | $50.00 | Overweight | Wells Fargo |
| 5/22/2023 | $35.00 → $38.00 | Buy | Jefferies |
| 9/19/2022 | $27.00 | Outperform | Wedbush |
| 8/26/2022 | $31.00 | Overweight | Piper Sandler |
| 11/12/2021 | $18.00 → $23.00 | Buy | Canaccord Genuity |
4 - Verona Pharma plc (0001657312) (Issuer)
4 - Verona Pharma plc (0001657312) (Issuer)
4 - Verona Pharma plc (0001657312) (Issuer)
4 - Verona Pharma plc (0001657312) (Issuer)
4/A - Verona Pharma plc (0001657312) (Issuer)
4 - Verona Pharma plc (0001657312) (Issuer)
LONDON and RALEIGH, N.C., May 21, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ:VRNA) ("Verona Pharma" or the "Company") announces that senior management will participate in fireside chats at the following conferences in June 2025: Jefferies Global Healthcare ConferenceDate: Wednesday, June 4, 2025Time: 11:05 a.m. ET / 4:05 p.m. BSTLocation: New York, NY Goldman Sachs 46th Annual Global Healthcare ConferenceDate: Monday, June 9, 2025Time: 2:40 p.m. ET / 7:40 p.m. BSTLocation: Miami, FL A webcast of each conference presentation will be available on the Events and Presentations link on the Investors page of the Company's website, www.veronapharma.com. For further information please
Analyses support Ohtuvayre® (ensifentrine) as a first-in-class selective dualinhibitor of PDE3 and PDE4 for a broad COPD population LONDON and RALEIGH, N.C., May 06, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ:VRNA) ("Verona" or the "Company"), a biopharmaceutical company focused on respiratory diseases, announces ten posters including seven additional analyses from its Phase 3 ENHANCE studies with Ohtuvayre (ensifentrine) for the treatment of chronic obstructive pulmonary disease ("COPD"), two from nonclinical studies, and one from a real-world data analysis, will be presented at the American Thoracic Society Conference ("ATS") 2025. The posters are published on the ATS website an
Total net revenue of $76.3 million from Q1 2025 driven by Ohtuvayre® net sales of $71.3 million (+95% vs Q4 2024) ~25,000 prescriptions filled in Q1 2025 Q1 2025 revenue exceeds operating expenses excluding non-cash charges Conference call today at 9:00 a.m. EDT / 2:00 p.m. BST LONDON and RALEIGH, N.C., April 29, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ:VRNA) ("Verona" or the "Company"), a biopharmaceutical company focused on respiratory diseases, announces its financial results for the first quarter ended March 31, 2025, and provides a corporate update. "The remarkably strong US launch of Ohtuvayre (ensifentrine) for the maintenance treatment of chronic obstructive pulmonar
TD Cowen initiated coverage of Verona Pharma with a rating of Buy and set a new price target of $100.00
Cantor Fitzgerald initiated coverage of Verona Pharma with a rating of Overweight and set a new price target of $80.00
ROTH MKM initiated coverage of Verona Pharma with a rating of Buy and set a new price target of $68.00
144 - Verona Pharma plc (0001657312) (Subject)
144 - Verona Pharma plc (0001657312) (Subject)
144 - Verona Pharma plc (0001657312) (Subject)